keyword
MENU ▼
Read by QxMD icon Read
search

Prolactinoma

keyword
https://www.readbyqxmd.com/read/27908263/prevalence-and-predictors-of-overweight-and-obesity-in-patients-with-pituitary-dysfunctions
#1
Birgit Harbeck, Sven Danneberg, Amir Hossein Rahvar, Heiner Mönig, Christian Stefan Haas
BACKGROUND: Patients with hypothalamic-pituitary disorders (HPD) may be of increased risk to develop overweight and obesity, thereby fostering cardiovascular events. However, it remains unclear if patients with pituitary dysfunctions per se have an increased risk of becoming obese. OBJECTIVE: The objective of this study was to evaluate prevalence and to identify possible predictors of overweight and obesity in patients with pituitary dysfunctions. METHODS: A total of 121 out-patients having various causes for HPD were assessed for height and body weight; body mass index (BMI) was calculated and correlated with clinical features...
November 30, 2016: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/27908214/pregnancy-and-tumor-outcomes-in-infertile-women-with-macroprolactinoma-on-cabergoline-therapy
#2
Ashu Rastogi, Sanjay K Bhadada, Anil Bhansali
Hyperprolactinemia and prolactinomas cause infertility in significant number of women. But, pregnancy may lead to post-partum remission of hyperprolactinemia. The data on pregnancy and tumor outcome in women with macroprolactinoma conceiving on Cabergoline (CAB) therapy is increasing but still less than with Bromocriptine. We studied the incidence of fetal malformations, hyperprolactinemia and tumor course after gestation in infertile women harboring macroprolactinoma, who conceived on CAB therapy during the year 2005-2015...
December 2, 2016: Gynecological Endocrinology
https://www.readbyqxmd.com/read/27901187/interactions-between-prolactin-and-kisspeptin-to-control-reproduction
#3
Jose Donato, Renata Frazão
Prolactin is best known for its effects of stimulating mammary gland development and lactogenesis. However, prolactin is a pleiotropic hormone that is able to affect several physiological functions, including fertility. Prolactin receptors (PRLRs) are widely expressed in several tissues, including several brain regions and reproductive tract organs. Upon activation, PRLRs may exert prolactin's functions through several signaling pathways, although the recruitment of the signal transducer and activator of transcription 5 causes most of the known effects of prolactin...
November 24, 2016: Archives of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/27866462/prolactinoma-and-pregnancy-a-series-of-cases-including-pituitary-apoplexy
#4
Ana Galvão, Daniela Gonçalves, Marta Moreira, Gonçalo Inocêncio, Clara Silva, Jorge Braga
The objective of this article is to evaluate the impact of pregnancy in women with prolactinoma, the possible consequences of therapy maintenance/discontinuation during pregnancy and to assess the type of delivery and maternal-foetal obstetrical outcome. A retrospective study of all pregnant women with prolactinoma in our Centre between 2006 and 2014 was made. We had 35 cases of pregnant women with prolactinoma, two of which had an episode of pituitary apoplexy during the second trimester. At the time of conception, most women were being treated with 5 mg bromocriptine...
November 21, 2016: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/27855233/a-macroprolactinoma-becoming-resistant-to-cabergoline-and-developing-atypical-pathology
#5
Emilia Sbardella, George Farah, Ahmed Fathelrahman, Simon Cudlip, Olaf Ansorge, Niki Karavitaki, Ashley B Grossman
: Pituitary adenomas are a common intracranial neoplasm, usually demonstrating a benign phenotype. They can be classified according to pathological, radiological or clinical behaviour as typical, atypical or carcinomas, invasive or noninvasive, and aggressive or nonaggressive. Prolactinomas account for 40-60% of all pituitary adenomas, with dopamine agonists representing the first-line treatment and surgery/radiotherapy reserved for drug intolerance/resistance or in neuro-ophthalmological emergencies...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27855229/late-presentation-of-acromegaly-in-medically-controlled-prolactinoma-patients
#6
Ekaterina Manuylova, Laura M Calvi, Catherine Hastings, G Edward Vates, Mahlon D Johnson, William T Cave, Ismat Shafiq
: Co-secretion of growth hormone (GH) and prolactin (PRL) from a single pituitary adenoma is common. In fact, up to 25% of patients with acromegaly may have PRL co-secretion. The prevalence of acromegaly among patients with a newly diagnosed prolactinoma is unknown. Given the possibility of mixed GH and PRL co-secretion, the current recommendation is to obtain an insulin-like growth factor-1 (IGF-1) in patients with prolactinoma at the initial diagnosis. Long-term follow-up of IGF-1 is not routinely done...
2016: Endocrinology, Diabetes & Metabolism Case Reports
https://www.readbyqxmd.com/read/27854004/erratum-to-prospective-long-term-study-of-the-effect-of-cabergoline-on-valvular-status-in-patients-with-prolactinoma-and-idiopathic-hyperprolactinemia
#7
Laurent Vroonen, Patrizio Lancellotti, Monica Tomé Garcia, Raluca Dulgheru, Matilde Rubio-Almanza, Ibrahima Maiga, Julien Magne, Patrick Petrossians, Renata Auriemma, Adrian F Daly, Albert Beckers
No abstract text is available yet for this article.
November 16, 2016: Endocrine
https://www.readbyqxmd.com/read/27849387/serum-levels-of-f%C3%A4-broblast-growth-factor-23-osteoproteger%C3%A4-n-and-receptor-act%C3%A4-vator-of-nuclear-factor-kappa-b-l%C3%A4-gand-rankl-%C3%A4-n-pat%C3%A4-ents-w%C3%A4-h-prolact%C3%A4-noma
#8
Muyesser Sayki Arslan, Mustafa Sahin, Melia Karakose, Esra Tutal, Oya Topaloglu, Bekir Ucan, Taner Demirci, Mustafa Caliskan, Seyda Sahingol, Mustafa Ozbek, Erman Cakal
PURPOSE: The aim of this study to was to evaluate the effect of fibroblast growth factor-23 (FGF-23), osteoprotegerin (OPG), receptor activator nuclear kB ligand (RANKL), and vitamin D hormones on bone loss in patients with hyperprolactinemia due to the pituitary prolactinoma. METHODS: 46 premenopausal female patients with prolactinoma and age and sex matched healthy controls (Group 3, n=20) were recruited to this cross sectional study. Prolactinoma patients were divided into two groups as patients newly diagnosed (Group 1, n=26), and under cabergoline treatment (Group 2, n=20)...
November 16, 2016: Endocrine Practice
https://www.readbyqxmd.com/read/27848079/cabergoline-and-prolactinomas-lack-of-association-between-drd2-polymorphisms-and-response-to-treatment
#9
Cbf Bueno, E B Trarbach, M D Bronstein, A Glezer
BACKGROUND: About 80% of prolactinomas respond to dopamine agonists (DA) with hormonal normalization and tumor shrinkage. Mechanisms of DA resistance include reduction of dopamine receptor subtype 2 (DRD2) expression, short and long isoform ratio and post-receptor mechanisms. It was suggested that polymorphisms in the gene encoding dopamine receptor subtype 2 gene (DRD2) could be associated with variable effectiveness of cabergoline (CAB). OBJECTIVE: To assess the influence of DRD2 polymorphisms in responsiveness of CAB treatment in patients with prolactinoma...
November 15, 2016: Pituitary
https://www.readbyqxmd.com/read/27830003/effect-of-bisphenol-a-on-occurrence-and-progression-of-prolactinoma-and-its-underlying-mechanisms
#10
Lanxiang Hao, Jing Zhang, Yonghong Zhang, Haitao Hu, Weiwei Shao, Xiaochen Zhang, Chunmei Geng, Yanyan Wang, Ling Jiang
OBJECTIVE: To investigate the effects of Bisphenol A (BPA) on prolactin (PRL) release, pituitary cell proliferation, prolactinoma formation in estrogen-sensitive Fischer 344 (F344) rats. MATERIALS AND METHODS: Four-week-old female F344 rats were orally administered with different concentrations of BPA or intraperitoneal injection of estradiol benzoate (estradiolbenzoate, E2) for 12 weeks. Bodyweight, blood RPL level and pituitary weights were observed and recorded...
2016: American Journal of Translational Research
https://www.readbyqxmd.com/read/27815961/successful-treatment-of-a-child-with-a-prolactin-secreting-macroadenoma-with-temozolomide
#11
James Felker, Brianna Patterson, David Wrubel, Anna Janss
Prolactinomas are a rare subset of brain tumors in pediatrics. We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Given the location of her tumor she was ineligible for surgical resection. Temozolomide (200 mg/m2×5 days each month) was administered with a dramatic and prolonged response in tumor size, prolactin level, and symptoms, with no side effects from treatment. We demonstrate the benefit of temozolomide in the treatment of a pediatric patient with prolactinoma...
December 1, 2016: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/27783196/management-of-prolactinomas-a-survey-of-physicians-from-the-middle-east-and-north-africa
#12
Salem A Beshyah, Ibrahim H Sherif, Farida Chentli, Amir Hamrahian, Aly B Khalil, Hussein Raef, Mohamed El-Fikki, Selim Jambart
BACKGROUND: Prolactinomas are the commonest functional tumors of the pituitary gland. There are still controversies regarding medical therapy in specific clinical situations. Patients may be managed by different specialists in the Middle East and North Africa (MENA) region and no data exist on patterns of clinical management. OBJECTIVES: To ascertain the diagnostic and therapeutic approaches to prolactinomas among relevant professionals from the MENA region. METHODS: An online survey of a large sample of physicians was conducted...
October 25, 2016: Pituitary
https://www.readbyqxmd.com/read/27773859/long-term-follow-up-of-primary-medical-versus-surgical-treatment-of-prolactinomas-in-men-effects-on-hyperprolactinemia-hypogonadism-and-bone-health
#13
Lukas Andereggen, Janine Frey, Robert H Andres, Marwan El-Koussy, Jürgen Beck, Rolf W Seiler, Emanuel Christ
OBJECTIVE: In men with prolactinomas, an impaired bone density is the principle consequence of hyperprolactinemia-induced hypogonadism. While dopamine (DA-) agonists are the first-line approach in prolactinomas, surgery can be considered in selected cases. In the present study, we aimed to investigate on the long-term control of hyperprolactinemia, hypogonadism and bone health comparing primary medical and surgical therapy in men who had not had prior DA-agonist treatment. METHODS: Retrospective case-note study of 44 consecutive men with prolactinomas and no prior DA-agonists managed in a single tertiary referral center...
October 20, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27770388/risk-of-malignant-neoplasms-in-acromegaly-a-case-control-study
#14
K Wolinski, A Stangierski, K Dyrda, K Nowicka, M Pelka, A Iqbal, A Car, M Lazizi, N Bednarek, A Czarnywojtek, E Gurgul, M Ruchala
PURPOSE: Acromegaly is a chronic disease resulting from pathological oversecretion of growth hormone and subsequently insulin growth factor-1. Several complications of the disease have been reported, including cardiovascular diseases, respiratory disorders but also increased risk of benign and malignant neoplasms. The aim of the study was to evaluate the risk of malignant neoplasms in the patients with acromegaly in comparison with the control group. PATIENTS AND METHODS: Medical documentation of acromegalic patients treated in one medical center between 2005 and 2016 has been analyzed...
October 21, 2016: Journal of Endocrinological Investigation
https://www.readbyqxmd.com/read/27757801/significance-of-surgical-management-for-cystic-prolactinoma
#15
Toshihiro Ogiwara, Tetsuyoshi Horiuchi, Alhusain Nagm, Tetsuya Goto, Kazuhiro Hongo
PURPOSE: It is generally accepted that dopamine agonists (DA) represent the first-line treatment for most patients with prolactinoma, and patients become candidates for surgical intervention when DA is contraindicated. Surgical indication for cystic prolactinoma remains controversial. This study was performed to investigate the significance of surgery for cystic prolactinoma. METHODS: A total of 28 patients that underwent transsphenoidal resection of prolactinoma between February 2004 and May 2016 were reviewed...
October 18, 2016: Pituitary
https://www.readbyqxmd.com/read/27734708/-multiple-endocrine-neoplasia-i-wermers-syndrome-forms-of-clinical-manifestation-5-case-studies
#16
Karolína Drbalová, Kateřina Herdová, Petr Krejčí, Monika Nývltová, Svatopluk Solař, Lenka Vedralová, Pavel Záruba, David Netuka, Petr Bavor
Multiple Endocrine Neoplasia (MEN) is a condition in which several endocrine organs of an individual are affected by adenoma, hyperplasia and less often carcinoma, either simultaneously or at different stages of life. Two existing syndromes, MEN1 and MEN2 (2A, 2B), in literature is also mentioned MEN4, are associated also with other non-endocrine disorders. MEN1 (Wermer syndrome) affects the pituitary, parathyroid, and pancreatic area. 95 % of patients show very early manifestation of hyperparathyroidism, often before 40 years of age...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27728195/incidental-finding-prolactinoma-macroadenoma
#17
A Krishna Murthy, G Vasavilatha, Srinivas Rao, Pranoy G
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27716353/the-risks-of-overlooking-the-diagnosis-of-secreting-pituitary-adenomas
#18
Thierry Brue, Frederic Castinetti
Secreting pituitary adenomas that cause acromegaly and Cushing's disease, as well as prolactinomas and thyrotroph adenomas, are uncommon, usually benign, slow-growing tumours. The rarity of these conditions means that their diagnosis is not familiar to most non-specialist physicians. Consequently, pituitary adenomas may be overlooked and remain untreated, and affected individuals may develop serious comorbidities that reduce their quality of life and life expectancy. Because many signs and symptoms of pituitary adenomas overlap with those of other, more common disorders, general practitioners and non-endocrinology specialists need to be aware of the "red flags" suggestive of these conditions...
October 6, 2016: Orphanet Journal of Rare Diseases
https://www.readbyqxmd.com/read/27710986/the-epidemiology-of-pituitary-adenomas-in-a-community-based-hospital-a-retrospective-single-center-study-in-saudi-arabia
#19
Khalid S Aljabri, Samia A Bokhari, Faisal Y Assiri, Muneera A Alshareef, Patan M Khan
BACKGROUND: Data on pituitary adenoma (PA) prevalence in Saudi Arabia are scarce. OBJECTIVE: To estimate the epidemiology of PA in a well-defined population. DESIGN: Retrospective analysis. SETTING: Departments of Endocrinology and Radiology at King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia. PATIENTS AND METHODS: Radiological and hormonal data of patients with pituitary adenoma by MRI were reviewed for the period January 2008 to December 2015...
September 2016: Annals of Saudi Medicine
https://www.readbyqxmd.com/read/27709470/prospective-long-term-study-of-the-effect-of-cabergoline-on-valvular-status-in-patients-with-prolactinoma-and-idiopathic-hyperprolactinemia
#20
Laurent Vroonen, Patrizio Lancellotti, Monica Tomé Garcia, Raluca Dulgheru, Matilde Almanza, Ibrahima Maiga, Julien Magne, Patrick Petrossians, Renata Auriemma, Adrian F Daly, Albert Beckers
Since the 1990's cabergoline has been the treatment of choice in prolactinoma, as it permits rapid and effective hormonal and tumor control in most cases. Evidence of cardiac valvulopathy was demonstrated in Parkinson's disease patients treated with dopamine agonists. Retrospective studies in prolactinoma patients treated with cabergoline at lower doses did not show such an effect. However, few prospective data with long-term follow-up are available. The aim of this study was to assess the safety of cabergoline regarding cardiac valvular status during prospective follow-up in patients treated for prolactinoma or idiopathic hyperprolactinemia...
October 5, 2016: Endocrine
keyword
keyword
12771
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"